Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus

INTRODUCTION: In a meta-analysis, we observed a significant 37% relative risk reduction in prospectively adjudicated major adverse cardiac events [MACEs, comprising of non-fatal myocardial infarction, non-fatal stroke, cardiovascular (CV) death] with vildagliptin vs. comparators in younger (< 65 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Marc, Kozlovski, Plamen, Paldánius, Päivi M., Foley, James E., Bhosekar, Vaishali, Serban, Carmen, Avogaro, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801217/
https://www.ncbi.nlm.nih.gov/pubmed/29134608
http://dx.doi.org/10.1007/s13300-017-0329-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801217/
https://www.ncbi.nlm.nih.gov/pubmed/29134608
http://dx.doi.org/10.1007/s13300-017-0329-5

Ejemplares similares